Tuberculosis recurrences and predictive factors in a vulnerable population in Catalonia

English version

Autoři: Sílvia Brugueras ^aff001; Vinicio-Israel Molina ^aff004; Xavier Casas ^aff004; Yoel-Domingo González ^aff004; Nuria Forcada ^aff004; Dora Romero ^aff004; Anna Rodés ^aff005; Maria-Neus Altet ^aff004; José Maldonado ^aff004; Mario Martin-Sánchez ^aff006; Joan A. Caylà ^aff007; Àngels Orcau ^aff001; Cristina Rius ^aff001; Joan-Pau Millet ^aff001
Působiště autorů: Epidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain ^aff001; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain ^aff002; Departamento de Pediatría, Obstetricia y Ginecología y Medicina Preventiva, Facultad de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain ^aff003; Serveis Clínics, Barcelona, Spain ^aff004; Agència de Salut Pública de Catalunya, Barcelona, Spain ^aff005; Preventive Medicine and Public Health Training Unit Parc de Salut Mar–Pompeu Fabra University—Public Health Agency of Barcelona (PSMar-UPF-ASPB), Barcelona, Spain ^aff006; Foundation of the Tuberculosis Research Unit of Barcelona (fuiTB), Barcelona, Spain ^aff007
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0227291

Souhrn

Background

Patients with a history of tuberculosis (TB) have a high probability of recurrence because long-term cure is not always maintained in successfully treated patients. The aim of this study was to identify the probability of TB recurrence and its predictive factors in a cohort of socially vulnerable patients who completed treatment in the TB referral center in Catalonia, which acts as the center for patients with social and health problems.

Methods

This retrospective open cohort study included all patients diagnosed with TB who were admitted and successfully treated in Serveis Clínics between 2000 and 2016 and who remained disease-free for a minimum of 1 year after treatment completion. We calculated the incidence density of TB recurrences per person-years of follow-up. We also estimated the cumulative incidence of TB recurrence at 1, 2, 5, and 10 years of follow-up. Bivariate analysis was conducted using Kaplan-Meier curves. Multivariate analysis was conducted using Cox regression. Hazard ratios (HR) were calculated with their 95% confidence intervals (95%CI).

Results

There were 839 patients and 24 recurrences (2.9%), representing 0.49 per 100 person-years. The probability of a recurrence was 0.63% at 1 year of follow-up, 1.35% at 2 years, and 3.69% at 5 years. The multivariate analysis showed that the predictive factors of recurrence were age older than 34 years (aHR = 3.90; CI = 1.06–14.34 at age 35–45 years and aHR = 3.88; CI = 1.02–14.80 at age >45 years) and resistance to at least one anti-TB drug (aHR = 2.91; CI = 1.11–7.65).

Conclusions

Attention should be paid to socially vulnerable persons older than 34 years with a previous episode of resistant TB. Surveillance resources should be directed toward adequately treated patients who nevertheless have a high risk of recurrence.

Klíčová slova:

Age groups – Extensively drug-resistant tuberculosis – HIV – HIV infections – Medical risk factors – Smoking habits – Spain – Tuberculosis

Zdroje

1. WHO. Global tuberculosis report 2018. Geneva; 2018.

2. Santín Cerezales M, Navas Elorza E. Tuberculosis in special populations. Enferm Infecc Microbiol Clin. 2011;29(Supl 1):20–5.

3. Caylà J a, Orcau A. Control of tuberculosis in large cities in developed countries: an organizational problem. BMC Med [Internet]. 2011 Jan [cited 2014 Dec 18];9(1):127. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3283473&tool=pmcentrez&rendertype=abstract

4. Lönnroth K, Migliori GB, Abubakar I, Ambrosio LD, Vries G De, Diel R, et al. action framework for low-incidence countries.:928–52.

5. Rosser A, Marx FM, Pareek M. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis. 2018;22(2):139–50. doi: 10.5588/ijtld.17.0590 29506610

6. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. 2007;11(October 2006):828–37.

7. Verver S, Warren RM, Beyers N, Richardson M, Spuy GD Van Der, Borgdorff MW, et al. Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New Tuberculosis. 2005;

8. Lambert M, Hasker E, Deun A Van, Roberfroid D, Boelaert M, Stuyft P Van Der. Recurrence in tuberculosis: relapse or reinfection? 2003;3(May):282–7.

9. Red Nacional de Vigilancia Epidemiológica. Ampliación de la definición de caso de tuberculosis en la red nacional de vigilancia epidemiológica. 2003.

10. Centers for Disease Control and Prevention CDC. Tuberculosis 2009 Case Definition. 2009.

11. Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S. Recurrence of tuberculosis in a low- incidence setting: a retrospective cross- sectional study augmented by whole genome sequencing. 2018;4–9.

12. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, et al. Recurrent Tuberculosis in the United States and Canada Relapse or Reinfection? 2004;170:1360–6. doi: 10.1164/rccm.200408-1081OC 15477492

13. Pettit AC, Kaltenbach LA, Maruri F, Cummins J, Smith TR, Warkentin JV, Griffin MR ST. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. 2011;15(July 2011):906–11.

14. Millet J-P, Shaw E, Orcau A, Casals M, Miró JM, Caylà J a. Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse? PLoS One [Internet]. 2013 Jan [cited 2014 Dec 8];8(6):e64898. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3679149&tool=pmcentrez&rendertype=abstract doi: 10.1371/journal.pone.0064898 23776440

15. Caylà J a, Rodrigo T, Ruiz-Manzano J, Caminero J a, Vidal R, García JM, et al. Tuberculosis treatment adherence and fatality in Spain. Respir Res [Internet]. 2009 Jan [cited 2014 Dec 18];10:121. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2794858&tool=pmcentrez&rendertype=abstract doi: 10.1186/1465-9921-10-121 19951437

16. Alsedà Graells M, Jansà López del Vallado J. Protocol per a la prevenció i el control de la tuberculosi. Documents de vigilància epidemiológica; Tuberculosi—Prevenció. [Internet]. 2008 [cited 2019 Apr 18]. Available from: www.gencat.cat/salut

17. World Health Organization (WHO). Treatment of tuberculosis: Guidelines 4th edition. [Internet]. Geneva: World Health Organization. 2003 [cited 2019 Apr 18]. Available from: https://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf;jsessionid=E9979DA618E9A71FF6C0E42AE5628257?sequence=1

18. Declaración de Helsinki de la AMM. Principios éticos para las investigaciones médicas en seres humanos. Asoc Médica Mund [Internet]. 2013; Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-evaluacion/fd-evaluacion-etica-investigacion/Declaracion-Helsinki-2013-Esp.pdf

19. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales [Internet]. Madrid: Noticias jurídicas BOE núm. 294. 2018 [cited 2019 Apr 18]. Available from: http://noticias.juridicas.com/base_datos/Laboral/632849-lo-3-2018-de-5-dic-proteccion-de-datos-personales-y-garantia-de-los-derechos.html

20. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Da [Internet]. Official Journal of the European Union Official Journal of the European Union, Vol. L119. 2016 [cited 2019 Apr 18]. p. 1–88. Available from: https://publications.europa.eu/en/publication-detail/-/publication/3e485e15-11bd-11e6-ba9a-01aa75ed71a1/language-en

21. Millet J-P, Orcau À, García de Olalla P, Casals M, Rius C, Cayla JA. Tuberculosis recurrence and its associated risk factors among successfully treated patients. 2009;63(10):799–804.

22. Crofts JP, Andrews NJ, Barker RD, Delpech V, Abubakar I. Risk factors for recurrent tuberculosis in England and Wales, 1998–2005. Thorax. 2010;65(4):310–4. doi: 10.1136/thx.2009.124677 20388755

23. Dobler C, Crawford A, Jelfs P, Gilbert G, Marks G. Recurrence of tuberculosis in a low-incidence setting. Eur respir J. 2009;33(1):160–7. doi: 10.1183/09031936.00104108 18829676

24. Rodés Monegal A, López Espinilla M, García Lebrón M. Informe anual 2016. Situació epidemiològica i tendència de l’endèmia tuberculosa a Catalunya [Internet]. 2018 [cited 2019 Apr 18]. Available from: http://salutpublica.gencat.cat/web/.content/minisite/aspcat/vigilancia_salut_publica/20180226_informe_anual_tuberculosi_2016.pdf

25. Schiroli C, Carugati M, Zanini F, Bandera A, Di S, Stuppino N, et al. Exogenous reinfection of tuberculosis in a low ‑ burden area. Infection. 2015;43:647–53. doi: 10.1007/s15010-015-0759-9 25754899

26. De Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, Van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis. 2003;7(2):145–52. 12588015

27. Caminero J, Pena M, Campos-Herrero M, Rodríguez J, Afonso O, Martin C, et al. Exogenous Reinfection with Tuberculosis on a European island with a moderate incidence of disease. 2001;163(3):717–20.

28. García de Viedma D, Marín M, Hernangómez S, Díaz M, Ruiz Serrano M, Alcalá L, et al. Tuberculosis Recurrences. Reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. 2002;162(16):1873–9.

29. El Sahly HM, Wright JA, Soini H, Bui TT, Escalante P. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis. 2004;8(3):333–40. 15139472

30. Chiang CY, Riley L. Exogenous reinfection in tuberculosis. Lancet Infect Dis. 2005;5:629–36. doi: 10.1016/S1473-3099(05)70240-1 16183517

31. Wang J, Lee L, Lai H, Hsu H, Liaw Y, Hsueh P, et al. Prediction of the Tuberculosis Reinfection Proportion from the Local Incidence. J Infect Dis [Internet]. 2007;196(2):281–8. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/518898 17570116

32. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. Aids. 2008;22(18):2527–33. doi: 10.1097/QAD.0b013e328311ac4e 19005276

33. Kim L, Moonan PK, Heilig CM, Woodruff RSY, Steve J, Haddad MB, et al. Factors associated with recurrent tuberculosis more than 12 months after treatment completion. Int J Tuberc Lung Dis. 2016;20(1):49–56. doi: 10.5588/ijtld.15.0442 26688528

34. Selassie AW, Pozsik C, Wilson D, Ferguson PL. Why pulmonary tuberculosis recurs: A population-based epidemiological study. Ann Epidemiol. 2005;15(7):519–25. doi: 10.1016/j.annepidem.2005.03.002 15921928

35. Centers for Disease Control and Prevention. Patients with Recurrent Tuberculosis. Morb Mortal Wkly Rep. 1982;30(52):645–7.

36. van der Heijden YF, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE, et al. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. Int J Tuberc Lung Dis. 2018;22(8):871–7. doi: 10.5588/ijtld.17.0766 29991395

37. Sun Y, Harley D, Vally H, Sleigh A. Impact of multidrug resistance on tuberculosis recurrence and long-term outcome in China. PLoS One. 2017;12(1):1–11.

38. Bestrashniy JRBM Nguyen VN, Nguyen TL Pham TL, Nguyen TA Pham DC, et al. Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: A nested case-control study. Int J Infect Dis [Internet]. 2018;74:31–7. Available from: doi: 10.1016/j.ijid.2018.06.013 29944930

39. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis. 2000;4(5):455–62. 10815740

40. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrnes G, et al. Tuberculosis recurrence and mortality after successful treatment: Impact of drug resistance. PLoS Med. 2006;3(10):1836–43.

41. Thomas A, Gopi P, Santha T, Chandrasekaran V, R S, N S, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis [Internet]. 2005;9(5):556–61. Available from: http://openurl.ingenta.com/content?genre=article&genre=article&genre=article&date=2005-05&issn=1027-3719&eissn=1815-7920&atitle=Predictors+of+relapse+among+pulmonary+tuberculosis+patients+treated+in+a+DOTS+programme+in+South+India.&volume=9&issue=5&spage= 15875929

42. Pascopella L, DeRiemer K, Watt JP, Flood JM. When tuberculosis comes back: Who develops recurrent tuberculosis in California? PLoS One. 2011;6(11).

43. Bandera A, Gori A, Catozzi L, Degli Esposti A, Marchetti G, Molteni C, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol. 2001;39(6):2213–8. doi: 10.1128/JCM.39.6.2213-2218.2001 11376059

44. Schiroli C, Franzetti F. La tubercolosi ricorrente: Recidiva o reinfezione esogena? Infez Med. 2013;21(4):251–60. 24335455

45. Blöndal K, Viiklepp P, Guomundsson LJ, Altraj A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(9):1228–33. doi: 10.5588/ijtld.12.0037 22748131

46. Yen YF, Yen MY, Lin YS, Lin YP, Shih HC, Li LH, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: A population-based study. Int J Tuberc Lung Dis. 2014;18(4):492–8. doi: 10.5588/ijtld.13.0694 24670708

47. Rosser A, Richardson M, Wiselka MJ, Free RC, Woltmann G, Mukamolova G V., et al. A nested case-control study of predictors for tuberculosis recurrence in a large UK Centre. BMC Infect Dis. 2018;18(1):1–9. doi: 10.1186/s12879-017-2892-9

48. Anaam MS, Ibrahim MIM, Al Serouri AW, Bassili A, Aldobhani A. A nested case-control study on relapse predictors among tuberculosis patients treated in Yemen’s NTCP. Public Heal Action. 2012;2(4):168–73.

49. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1124–30. doi: 10.1164/rccm.200407-905OC 15374844

50. Interrante JD, Haddad MB, Kim L, Gandhi NR. Exogenous reinfection as a cause of late recurrent tuberculosis in the United States. Ann Am Thorac Soc. 2015;12(11):1619–26. doi: 10.1513/AnnalsATS.201507-429OC 26325356

Tuberculosis recurrences and predictive factors in a vulnerable population in Catalonia

Souhrn

Background

Methods

Results

Conclusions

Klíčová slova:

Zdroje

PLOS One

INSIGHTS from European Respiratory Congress

Současné pohledy na riziko v parodontologii

Svět praktické medicíny 3/2024 (znalostní test z časopisu)

Kardiologické projevy hypereozinofilií

Střevní příprava před kolonoskopií